Close Menu

NEW YORK (GenomeWeb) – A health economic study sponsored by Biodesix has found that the company's Veristrat lung cancer test could potentially decrease patient treatment costs.

Published this week in the journal Lung Cancer, the study found that using Veristrat to guide patient therapy in cases of advanced non-small cell lung cancer decreased the total lifetime direct medical cost per patient by $135.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US. 

A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports. 

Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring. 

In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.